Skye Bioscience Inc.
10/24/2024 | Press release | Distributed by Public on 10/24/2024 15:00
Proxy Results Form 8 K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As described in 5.07 below, on October 22, 2024, at the special meeting of stockholders (the "Special Meeting") of Skye Bioscience, Inc. (the "Company"), the Company's stockholders voted to approve the second amendment and restatement of the Company's Amended and Restated 2014 Omnibus Incentive Plan to increase the number of shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), issuable thereunder by 1,535,655, while retaining the automatic share replenishment feature of the plan, increase the number of incentive stock options that may be granted thereunder to 4,000,000, extend the expiration date of the plan to September 10, 2034, update the name of the plan to the "Skye Bioscience, Inc. Amended and Restated Omnibus Incentive Plan" and make certain housekeeping amendments (as so amended and restated, the "Amended and Restated Plan") The Amended and Restated Plan was previously approved by the Company's board of directors, subject to approval by the stockholders of the Company at the Special Meeting, and became effective upon such stockholder approval.
The material terms of the Amended and Restated Plan were described in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on September 23, 2024 (the "Proxy Statement"), which description is incorporated by reference herein. The descriptions of the Amended and Restated Plan in the Proxy Statement and herein are qualified in their entirety by reference to the Amended and Restated Plan, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.